SGHT - Sizing Up Sight Sciences
- Shares of ophthalmic medical device concern Sight Sciences, Inc. have fallen 55% from their IPO pricing and 70% from their all-time high as the market shuns high-growth, profitless stocks.
- Owing to this decline, the company now trades at 4x FY22E sales net of net cash, even though that estimate represents a 45% increase over FY21.
- The company has nearly 90% gross margin for its Surgical Glaucoma unit and a chance to pioneer its own $5 billion market opportunity.
- The stock has also seen some recent insider buying. A full investment analysis follows in the paragraphs below.
For further details see:
Sizing Up Sight Sciences